Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
VitaNova Life Sciences's net current asset value per share for the quarter that ended in Apr. 2026 was $0.24.
The historical rank and industry rank for VitaNova Life Sciences's Net Current Asset Value or its related term are showing as below:
VNOV'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.35 Med: 5.75 Max: 13.85
Current: 5.75
During the past 10 years, the highest Price-to-Net-Current-Asset-Value Ratio of VitaNova Life Sciences was 13.85. The lowest was 2.35. And the median was 5.75.
VNOV's Price-to-Net-Current-Asset-Value is not ranked
in the Medical Distribution industry.
Industry Median: 3.19
vs VNOV: 5.75
VitaNova Life Sciences (OTCPK:VNOV) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
VitaNova Life Sciences Net Current Asset Value Related Terms
VitaNova Life Sciences Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for VitaNova Life Sciences's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VitaNova Life Sciences Net Current Asset Value Chart
VNOV vs HKPD, COSM, SNYR: Net Current Asset Value Comparison
For the Medical Distribution subindustry, VitaNova Life Sciences's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VitaNova Life Sciences Price-to-Net-Current-Asset-Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, VitaNova Life Sciences's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where VitaNova Life Sciences's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.24 mean?
VitaNova Life Sciences (VNOV) has a Net Current Asset Value of $0.24 as of Apr. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on VitaNova Life Sciences and its competitors. This is 96% below median its historical median of 5.75. Over the past decade, VitaNova Life Sciences' Net Current Asset Value has ranged from 2.35 to 13.85.
Is VitaNova Life Sciences' Net Current Asset Value too high?
VitaNova Life Sciences' current Net Current Asset Value of $0.24 is 96% below median its 10-year median of 5.75. Over the past 10 years, this metric has ranged from a low of 2.35 to a high of 13.85. The Medical Distribution industry median Net Current Asset Value is 3.19. VitaNova Life Sciences' value of $0.24 is 92.5% below this industry median. Overall, VitaNova Life Sciences has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does VitaNova Life Sciences' Net Current Asset Value compare to HKPD and COSM?
VitaNova Life Sciences' Net Current Asset Value of $0.24 can be compared against companies in the Medical Distribution industry. The industry median Net Current Asset Value is 3.19. VitaNova Life Sciences' value of $0.24 is 92.5% below this benchmark. Historically, VitaNova Life Sciences' own Net Current Asset Value has ranged from 2.35 to 13.85 over the past decade. While the company's 10-year median is 5.75 vs. the industry median of 3.19, VitaNova Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Distribution company?
The median Net Current Asset Value among Medical Distribution companies is 3.19, based on 77 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VitaNova Life Sciences's current Net Current Asset Value of $0.24 is 92.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on VitaNova Life Sciences and its competitors. For the Medical Distribution industry, the median Net Current Asset Value is 3.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VitaNova Life Sciences's current Net Current Asset Value is $0.24, which is 96% below median its own 10-year median of 5.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VitaNova Life Sciences stock overvalued right now?
VitaNova Life Sciences (VNOV) has a current Net Current Asset Value of $0.24. The stock's GF Value™ is $5.95, compared to a current price of $1.38 — trading 76.8% below its estimated fair value. The current Net Current Asset Value is $0.24, which is 96% below median its 10-year median of 5.75 and 92.5% below the Medical Distribution industry median of 3.19. VitaNova Life Sciences' overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For VitaNova Life Sciences (VNOV), the current Net Current Asset Value is $0.24 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VitaNova Life Sciences (VNOV) Overvalued in 2026?
Based on GuruFocus' analysis, VitaNova Life Sciences stock appears to be undervalued.
The current stock price of $1.38 is trading 76.8% below its estimated GF Value™ of $5.95.
Key valuation signals for VNOV:
Net Current Asset Value: $0.24 (96% below median its 10-year median of 5.75)
GF Value™: $5.95 vs. price of $1.38 (76.8% below fair value)
Industry Position: 92.5% below the Medical Distribution median
No single metric tells the full story. See the VNOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VitaNova Life Sciences Corp, formerly Yijia Group Corp provides business consulting services to domestic and international customers. The Company provides consulting services to its clients with regards to funding and other financial matters.The company's operating segments are The consulting services Segment mainly provides consulting advisory services in management, business, accounting and finance; and the Healthcare Segment mainly provides healthcare products and health consultation services to customers. The sale and distribution of healthcare products, such as Nicotinamide Riboside capsules, has only one performance obligation under the fixed-fee arrangements. and the majority of its revenue generates from Sales of healthcare products.
51GF Score
Get the complete analysis for VNOV
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VNOV has been successfully added to your 
